Abstract
As the longest war in American history draws to a close, an unprecedented number of service members and veterans are seeking care for health challenges related to transitioning home and to civilian life. Congressionally mandated screening for mental health concerns in the Department of Defense (DoD), as well as screening efforts Veterans Affairs (VA) facilities, has been established with the goal of decreasing stigma and ensuring service members and veterans with depression and posttraumatic stress disorder (PTSD) receive needed treatment. Both the DoD and VA have also developed integrated behavioral health in primary-care based initiatives, which emphasize PTSD screening, treatment, and care coordination. This article discusses the rationale for population-level deployment-related mental health screening, recent changes to screening frequency, commonly used screening instruments such as the primary care PTSD screen (PC-PTSD), PTSD checklist (PCL), and Davidson Trauma Scale (DTS); as well as the strengths/limitations of each, and recommended cut-off scores based on expected PTSD prevalence.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Hoge C. Once a Warrior—Always a Warrior: Navigating the Transition from Combat to Home, Including Combat Stress, PTSD, and mTBI Guilford, CT. Globe Pequot Press; 2010.
Kok B, Herrell R, Thomas J, Hoge C. Posttraumatic stress disorder associated with combat service in Iraq or Afghanistan: reconciling prevalence differences between studies. J Nerv Ment Dis. 2012;200(5):440–50. This article provides a meta-analysis of studies of PTSD prevalence associated with military service in Iraq and Afghanistan. It provides a good explanation for why prevalences have varied widely in different studies.
Hoge C, Grossman S, Auchterlonie J, Riviere L, Milliken C, et al. PTSD Treatment for Soldiers After Combat Deployment: Low Utilization of Mental Health Care and Reasons for Dropout. Psychiatr Serv. 2014. doi:10.1176/appi.ps.201300307. This article provides data consistent with several studies in Veterans Health Administration facilities highlighting continued problems with low utilization of mental health services and reasons for dropping out of care. The paper provides data on reasons for drop-out and the authors argue that enhancing engagement in care is the most important factor in improving overall effectiveness of treatment.
Miliken C, Auchterlonie J, Hoge C. Longitudinal Assessment of Mental Health Problems Among Active and Reserve Component Soldiers Returning From the Iraq War. JAMA. 2007;298(18):2141–8.
Warner C, Appenzeller G, Grieger T, Belenkiy S, Breitbach J, et al. Importance of Anonymity to Encourage Honest Reporting in Mental Health Screening After Combat Deployment. Arch Gen Psychiatr. 2011;68(10):1065–71. This article highlights the problem with underreporting of mental health symptoms by service members on manditory deployment-related military screenings, as compared to data collected using anonymous surveys.
Hoge C, Auchterlonie J, Milliken C. Mental Health Problems, Use of Mental Health Services, and Attrition From Military Service After Returning From Deployment to Iraq or Afghanistan. JAMA. 2006;295:1023–32.
Brady K, Pearlstein T, Asnis G, Baker D, Rothbaum B, et al. Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder. JAMA. 2000;283(14):1837–44.
Davidson J, Baldwin D, Stein D, Kuper E, Benattia I, et al. Treatment of Posttraumtic Stress Disorder With Venlafaxine Extended Release: A 6-Month Randomized Controlled Trial. Arch Gen Psychiatry. 2006;63:1158–65.
Davidson J, Pearlstein T, Londborg P, Brady K, Rothbaum B, et al. Efficacy of Sertraline in Preventing Relapse of Posttraumatic Stress Disorder: Results of a 28-Week Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2001;158:1974–81.
Davidson J, Rothbaum B, van der Kolk B, Sikes C, Farfel G. Multicenter, Double-blind Comparison of Sertraline and Placebo in the Treatment of Posttraumatic Stress Disorder. Arch Gen Psychiatry. 2001;58:485–92.
GlaxoSmithKline. A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder. Unpublished. 2001.
Martenyi F, Brown E, Zhang H, Koke S, Prakash A. Fluoxetine v placebo in prevention of relapse in post-traumatic stress disorder. BJP. 2002;181:315–20.
Martenyi F, Brown E, Zhang H, Prakash A, Koke S. Fluoxetine Versus Placebo in Posttraumatic Stress Disorder. J Clin Psychiatry. 2002;63(3):199–206.
Martenyi F, Soldatenkova V. Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial. Eur Neuropsychopharmacol. 2006;16:340–9.
Raskin M, Peskind E, Kanter E, Petrie E, Radant A. Reduction of Nightmares and Other PTSD Symptoms in Combat Veterans by Prazosin: A Placebo-Controlled Study. Am J Psychiatry. 2003;160:371–3.
Raskin M, Peterson K, Williams T, Hoff D, Hart K, et al. A Trial of Prazosin for Combat Trauma PTSD With Nightmares in Active-Duty Soldiers Returned From Iraq and Afghanistan. Am J Psychiatry. 2013;170:1003–10. This article is important from a pharmacotherapy standpoint in that it is the first demonstration of efficacy with twice daily prazosin dosing.
Schneier F, Neria Y, Pavlicova M, Hembree E, Jung Suh E, et al. Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial. Am J Psychiatry. 2012;169:80–8.
Shalev A, Freedman S, Peri T, Brandes D, Sahar T, Orr S. Prospective Study of Posttraumatic Stress Disorder and Depression Following Trauma. Am J Psychiatry. 1998;155:630–7.
Shih R, Schell T, Hambarsoomian K, Marshall G, Belzberg H. Prevalence of PTSD and Major Depression Following Trauma-Center Hospitalization. J Trauma. 2010;69(6):1560–6.
van der Kolk B, Spinazzola J, Blaustein M, Hopper J, Hopper E, et al. A Randomized Clinical Trial of Eye Movement Desensitization and Reprocessing (EMDR), Fluoxetine, and Pill Placebo in the Treatment of Posttraumatic Stress Disorder: Treatment Effects and Long-Term Maintenance. J Clin Psychiatry. 2007;68:37–46.
Hoge C, Terhakopian A, Castro C, Messer S, Engel C. Association of Posttraumatic Stress Disorder With Somatic Symptoms, Health Care Visits, and Absenteeism Among Iraq War Veterans. Am J Psychiatry. 2007;164:150–3.
Frierson R. Combat-Related Posttraumatic Stress Disorder and Criminal Responsibility Determinations in the Post-Iraq Era: A Review and Case Report. J Am Acad Psychiatry Law. 2013;41:79–84.
Terhakopian A, Sinaii N, Engel C, Schnurr P, Hoge C. Estimating Population Prevalence of Posttraumatic Stress Disorder: An Example Using the PTSD Checklist. J Trauma Stress. 2008;21(3):290–300.
McDonald S, Beckham J, Morey R, Calhoun P. The validity and diagnostic efficiency of the Davidson Trauma Scale in military veterans who have served since September 11th, 2001. J Anxiety Disord. 2009;23:247–55.
National Defense Authorization Act (NDAA), F.Y. 1998, H.R.1119, Section 765.
Ronald W. Reagan National Defense Authorization Act (NDAA), F.Y. 2005, H.R. 4200, Section 723.
National Defense Authorization Act (NDAA), F.Y. 2012, H.R. 4310, Sections 582 & 1212., U.S. Congress.
Warner C, Appenzeller G, Parker J, Warner C, Hoge C. Effectiveness of Mental Health Screening and Coordination of In-Theater Care Prior to Deployment to Iraq: A Cohort Study. Am J Psychiatry. 2011;168:378–85. This article is important because it demonstrates the effectiveness of coordinating mental health services between the operational and homefront environments in addition to screening.
Engel C, Oxman T, Yamamato C, Gould D, Barry S, et al. RESPECT-Mil: Feasibility of a Systems-Level Coliaborative Care Approach to Depression and Post-Traumatic Stress Disorder in Military Primary Care. Mil Med. 2008;173(10):935–40.
Oxman T. RESPECT.Mil: Behavioral Health Specialist Manual. In: Excellence RMCo, editor. 2008
Treatment for Posttraumatic Stress Disorder in Military and Veteran Populations: Initial Assessment. Institute of Medicine. National Academy of Sciences. 2012.
Bliese P, Wrigh K, Adler A, Castro C, Hoge C, et al. Validating the Primary Care Posttraumatic Stress Disorder Screen and the Posttraumatic Stress Disorder Checklist With Soldiers Returning From Combat. J Consult Clin Psychol. 2008;76(2):272–81.
Prins A, Ouimette P, Kimerling R, Cameron R, Hugelshofer D. The primary care PTSD screen (PC-PTSD): Development and operating characteristics. Prim Care Psychiatry. 2004;9:9–14.
Forbes D, Creamer M, Biddle D. The validity of the PTSD checklist as a measure of symptomatic change in combat-related PTSD. Behav Res Ther. 2001;39:977–86.
Dobie D, Kivlahan D, Maynard C, Bush K, McFall M. Screening for post-traumatic stress disorder in female Veteran's Affairs patients: validation of the PTSD checklist. Gen Hosp Psychiatry. 2002;24:367–74.
Blanchard E, Jones-Alexander J, Buckley T, Forneris C. Psychometric Properties of the PTSD Checklist (PCL). Behav Res Ther. 1996;34(8):669–73.
Cook J, Elhai J, Arean P. Psychometric Properties of the PTSD Checklist With Older Primary Care Patients. J Trauma Stress. 2005;18(4):371–6.
Passos R, Figueira I, Mendlowicz M, Moraes C, Coutinho E. Exploratory factor analysis of the Brazilian version of the Post-Traumatic Stress Disorder Checklist – Civilian Version (PCL-C). Rev Bras Psiquiatr. 2012;34:155–61.
Semage S, Sivayogan S, Forbes D, O'Donnell M, Monaragala R, et al. Cross-cultural and factorial validity of PTSD check list - military version (PCL-M) in Sinhalese language. Eur J Psychotraumatol. 2013;4:19707.
Monson C, Gradus J, Young-Xu Y, Schnurr P, Price J. Change in posttraumatic stress disorder symptoms: Do clinicians and patients agree? Psychol Assess. 2008;20(2):131–8.
Wilkins K, Lang A, Norman S. Synthesis of the Psychometric Properties of the PTSD Checklist (PCL) Military, Civilian, and Specific Versions. Depress Anxiety. 2011;28:596–606. This article is an excellent discussion of the strengths, weaknesses, and limitations of the PCL in its various forms.
Hoge C, Castro C, Messer S, McGurk D, Cotting D. Combat Duty in Iraq and Afghanistan, Mental Health Problems, and Barriers to Care. N Engl J. 2004;351:13–22.
Thomas J, Wilk J, Riviere L, McGurk D, Castro C. Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Arch Gen Psychiatr. 2010;67(6):614–23.
Bodkin J. Is PTSD caused by traumatic stress? J Anxiety Disord. 2007;21:176–82.
McDonald S, Thompson N, Stratton K, Calhoun P, MIRECC W. Diagnostic accuracy of three scoring methods for the Davidson Trauma Scale among U.S. military Veterans. J Anxiety Disord. 2014;28(2):160–8.
Davidson J, Tharwani H, Connor K. Davidson Trauma Scale (DTS): Normative scores in the general population and effect sizes in placebo-controlled SSRI trials. Depress Anxiety. 2002;15(2):75–8.
Foa E, Cashman L, Jaycox L, Perry K. The validation of a self-report measure of posttraumatic stress disorder: The Posttraumatic Diagnostic Scale. Psychol Assess. 1997;9(4):445–51.
Shoeb M, Weinstein H, Mollica R. The Harvard Trauma Questionnaire: Adapting a Cross-Cultural Instrument for Measuring Torture, Trauma, and Posttraumatic Stress Disorder in Iraqi Refugees. Int J Soc Psychiatry. 2007;53(5):447–63.
Zhang L, Li H, Benedek D, Li X, Ursano R. A strategy for the development of biomarker tests for PTSD. Med Hypotheses. 2009;73(3):404–9.
Su T, Zhang L, Chung M, Chen Y, Bi Y, Chou Y. Levels of the potential biomarker p11 in peripheral blood cells distinguish patients with PTSD from those with other major psychiatric disorders. J Psychiatr Res. 2009;43(13):1078–85.
van Zuiden M, Geuze E, Willemen H, Vermetten E, Maas M, Heijnen C, et al. Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deployment. Am J Psychiatry. 2011;168(89–96):89.
von Känel R, Begré S, Abbas C, Saner H, Gander M, Schmid J. Inflammatory biomarkers in patients with posttraumatic stress disorder caused by myocardial infarction and the role of depressive symptoms. Neuroimmunomodulation. 2009;17(1):39–46.
Heim C, Ehlert U, Hellhammer D. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 2000;25(1):35.
Compliance with Ethics Guidelines
ᅟ
Conflict of Interest
Daniel J. Lee, Christopher H. Warner, and Charles W. Hoge declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Military Mental Health
Rights and permissions
About this article
Cite this article
Lee, D.J., Warner, C.H. & Hoge, C.W. Advances and Controversies in Military Posttraumatic Stress Disorder Screening. Curr Psychiatry Rep 16, 467 (2014). https://doi.org/10.1007/s11920-014-0467-7
Published:
DOI: https://doi.org/10.1007/s11920-014-0467-7